New York State Common Retirement Fund Raises Position in Heron Therapeutics, Inc. $HRTX

New York State Common Retirement Fund increased its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 46.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,576,716 shares of the biotechnology company’s stock after purchasing an additional 816,671 shares during the quarter. New York State Common Retirement Fund’s holdings in Heron Therapeutics were worth $3,247,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. CWM LLC increased its position in Heron Therapeutics by 738.0% in the third quarter. CWM LLC now owns 45,015 shares of the biotechnology company’s stock worth $57,000 after buying an additional 39,643 shares during the last quarter. Congress Park Capital LLC lifted its position in shares of Heron Therapeutics by 27.4% during the 3rd quarter. Congress Park Capital LLC now owns 2,890,157 shares of the biotechnology company’s stock valued at $3,642,000 after buying an additional 621,908 shares during the last quarter. B. Riley Wealth Advisors Inc. bought a new position in shares of Heron Therapeutics during the 2nd quarter worth $26,000. Captrust Financial Advisors purchased a new stake in Heron Therapeutics in the 2nd quarter worth about $99,000. Finally, BNP Paribas Financial Markets increased its holdings in Heron Therapeutics by 11.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 305,843 shares of the biotechnology company’s stock worth $633,000 after acquiring an additional 31,898 shares during the last quarter. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Analysts Set New Price Targets

HRTX has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Heron Therapeutics in a report on Friday, January 9th. Jefferies Financial Group restated a “buy” rating on shares of Heron Therapeutics in a research note on Tuesday, November 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $4.50.

Heron Therapeutics Trading Up 4.1%

Shares of Heron Therapeutics stock opened at $1.26 on Friday. The company’s 50-day moving average price is $1.34 and its 200-day moving average price is $1.33. The company has a current ratio of 2.56, a quick ratio of 1.78 and a debt-to-equity ratio of 19.89. Heron Therapeutics, Inc. has a 12-month low of $1.00 and a 12-month high of $2.68. The company has a market cap of $231.03 million, a price-to-earnings ratio of -14.00 and a beta of 1.25.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.